Nrf2在EGFR基因突变肺腺癌中的表达及其与EGFR-TKIs疗效间的相关性研究

BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become first-line treatment drugs for lung adenocarcinoma patients with EGFR gene mutations. Significant interindividual variations in response rate, progression-free survival (PFS), and overall su...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2014
Materias:
临床研究
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000052/
https://www.ncbi.nlm.nih.gov/pubmed/24581168
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.02.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000052/
https://www.ncbi.nlm.nih.gov/pubmed/24581168
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.02.15

Ejemplares similares